It is exciting that multiple preclinical studies have demonstrated that MEK inhibitors can inhibit the proliferation of CRC cells with KRAS or BRAF mutations in vitro and in vivo, reversing drug resistance mediated by KRAS or BRAF mutations [21,22]. Here, BRAF is linked to colorectal carcinoma.